Recent 8-K filings for HSCS
Highest-materiality recent filing
Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments
- Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.
- The reverse stock split affects both common stock and warrants, with split-adjusted trading expected at market open on May 17, 2024.
-
HeartSciences COO and Board Member Mark Hilz passes away at 67
Mark Hilz, COO, Corporate Secretary and Board member, died April 1, 2026 after an illness.
-
HeartSciences issues $3.6M 12% promissory note to Streeterville Capital, netting $3M
Company entered Note Purchase Agreement with Streeterville Capital for $3,605,000 promissory note, netting $3,000,000 after $600,000 OID and $5,000 expenses.
-
Board approved Amendment No. 3 to 2023 Equity Incentive Plan, increasing authorized shares from 1M to 1.25M plus annual evergreen.
-
HeartSciences extends loan maturity to 2026, raises $6.7M in Reg A, exchanges $2.06M debt for equity
Loan maturity extended to Sept 30, 2026; accrued interest payment structure amended.
-
HeartSciences regains Nasdaq minimum equity compliance; delisting risk cleared
Received formal notice on Sept 16, 2025 that it regained compliance with Nasdaq Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
-
HeartSciences reports Q1 FY2026 with $2.8M cash; launches MyoVista Insights platform
No meaningful revenue for Q1 FY2026; cash and equivalents $2.8M, shareholders' equity $3.1M as of July 31, 2025.
-
HeartSciences raises $5.4M in Reg A offering, exchanges $1.8M debt for shares
Received $5.4M gross proceeds from Reg A offering of units at $3.50; 1,556,409 units issued as of Sep 5, 2025.
-
HeartSciences raises $5.2M in Reg A offering and exchanges $1.655M debt for equity
Gross proceeds of $5.2M from offering of 1,484,440 Units at $3.50/Unit as of Aug 22, 2025.
-
HeartSciences reports no FY2025 revenue, $1.1M cash; advances MyoVista platform
Zero revenue for fiscal year ended April 30, 2025; cash and equivalents $1.1M, shareholders' equity $0.2M.
-
FDA granted Breakthrough Device designation for HeartSciences' Aortic Stenosis AI-ECG algorithm.
-
Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M
Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
-
HeartSciences receives Nasdaq delisting notice over $1.79M equity vs $2.5M minimum
Received Nasdaq deficiency letter on March 19, 2025: stockholders' equity of $1.79M below $2.5M minimum.
-
HeartSciences Q3 FY2025 no revenue, cash $2.6M; FDA submission for MyoVista device expected H1 2025
No revenue for Q3 FY2025; cash and equivalents $2.6M, shareholders' equity $1.8M as of Jan 31, 2025.
-
HeartSciences withdraws S-1 registration statement for proposed public offering
Withdrew Registration Statement on Form S-1 filed June 7, 2023 (as amended).
-
Cash and cash equivalents of $4.3M as of July 31, 2024; shareholders' equity of $5.9M.
-
Issued $2.51M unsecured promissory note to Streeterville Capital; 8.5% interest, 18-month maturity, $500K OID.
-
HeartSciences regains Nasdaq minimum bid price compliance; hearing cancelled
Nasdaq notified HeartSciences on June 3, 2024 that it regained compliance with $1.00 minimum bid price requirement.
-
Heart Test Labs obtains temporary stay of Nasdaq delisting; hearing set for June 27
Nasdaq delisting action stayed pending oral hearing on June 27, 2024.
-
Heart Test Laboratories files 8-K/A to clarify reverse stock split and warrant adjustments
Heart Test Laboratories filed Amendment No. 1 to Form 8-K to clarify details of its 1-for-100 reverse stock split.
-
Heart Test Laboratories to effect 1-for-100 reverse stock split on May 17, 2024
Reverse stock split of common stock and warrants at 1-for-100 ratio, effective at market open on May 17, 2024.
-
Received Nasdaq staff determination to delist under Low Priced Stocks Rule (closing bid ≤$0.10 for 10 consecutive days).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material